SEARCH:   Advanced

Blood, 1 November 2005, Vol. 106, No. 9, pp. 2977-2981. Prepublished online as a Blood First Edition Paper on July 14, 2005; DOI 10.1182/blood-2005-02-0691. This Article Full Text Full Text (PDF) All Versions of this Article: 2005-02-0691v1 106/9/2977    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Richardson, P. G. G. Articles by Anderson, K. C. Search for Related Content PubMed PubMed Citation Articles by Richardson, P. G. G. Articles by Anderson, K. C. Related Collections Neoplasia Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma Paul Gerard Guy Richardson, Bart Barlogie, James Berenson, Seema Singhal, Sundar Jagannath, David Irwin, S. Vincent Rajkumar, Teru Hideshima, Hugh Xiao, Dixie Esseltine, David Schenkein, Kenneth C. Anderson, for the SUMMIT Investigators From the Dana-Farber Cancer Institute, Boston, MA; University of Arkansas for Medical Sciences, Little Rock, AR; Cedars-Sinai Medical Center, Los Angeles, CA; Northwestern Memorial Hospital, Chicago, IL; St Vincent's Comprehensive Cancer Center, New York, NY; Alta Bates Cancer Center, Berkeley, CA; Mayo Clinic, Rochester, MN; and Millenium Pharmaceuticals, Inc., Cambridge, MA. Bortezomib, a potent and reversible proteasome inhibitor, affects the myeloma cell and its microenvironment, resulting in down-regulation of growth and survival signaling pathways and durable responses in patients with relapsed and refractory myeloma. Potential associations between baseline parameters and outcomes with bortezomib were explored in 202 patients who received bortezomib 1.3 mg/m2 twice weekly for 2 weeks every 3 weeks for up to 8 cycles in a phase 2 trial. Using European Group for Blood and Marrow Transplantation criteria, the response rate (complete or partial response) to bortezomib alone was 27% and was not associated with sex, race, performance status, isotype, chromosome 13 deletion, number or type of previous therapies, or concentration of hemoglobin or 2-microglobulin. By multivariate analysis, factors associated with lower response were being age 65 or older versus younger than 65 (19% vs 32%; P < .05) and plasma-cell infiltration in bone marrow greater than 50% versus 50% or less (20% vs 35%; P < .05). Factors that may be indicative of tumor burden (bone marrow plasma-cell infiltration greater than 50%, hypoalbuminemia, thrombocytopenia) were predictive of overall survival. Chromosome 13 deletion and elevated 2-microglobulin, generally considered poor prognostic factors, were not predictive of poor outcome with bortezomib in this study. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: A. Palumbo, F. Gay, S. Bringhen, A. Falcone, N. Pescosta, V. Callea, T. Caravita, F. Morabito, V. Magarotto, M. Ruggeri, et al. Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma Ann. Onc., June 1, 2008; 19(6): 1160 - 1165. [Abstract] [Full Text] [PDF] P. G. Richardson, C. Mitsiades, R. Schlossman, N. Munshi, and K. Anderson New Drugs for Myeloma Oncologist, June 1, 2007; 12(6): 664 - 689. [Abstract] [Full Text] [PDF] A. Palumbo, M. T. Ambrosini, G. Benevolo, P. Pregno, N. Pescosta, V. Callea, C. Cangialosi, T. Caravita, F. Morabito, P. Musto, et al. Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma Blood, April 1, 2007; 109(7): 2767 - 2772. [Abstract] [Full Text] [PDF] W.-Z. Ying, H.-G. Zhang, and P. W. Sanders EGF Receptor Activity Modulates Apoptosis Induced by Inhibition of the Proteasome of Vascular Smooth Muscle Cells J. Am. Soc. Nephrol., January 1, 2007; 18(1): 131 - 142. [Abstract] [Full Text] [PDF] P. G. Richardson, T. Hideshima, and K. C. Anderson Plasma cell dyscrasias ASH Self-Assessment Program, January 1, 2007; 2007(1): 298 - 327. [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020